Abbott Laboratories Beats Q2 Earnings Estimates

by webmaster

Abbott Laboratories, a leading diagnostics and medical-device company, saw its stock (ABT) rise 1.6% in premarket trade on Thursday. Despite lower earnings compared to the previous year, Abbott Laboratories managed to surpass analyst estimates.

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Earnings Report Highlights

In the second quarter, the company reported a net income of $1.375 billion, equivalent to 78 cents per share. This is a decrease from the $2.018 billion, or $1.14 per share, recorded during the same period last year. However, adjusted per-share earnings came in at $1.08, exceeding the FactSet consensus of $1.05.

Sales Performance

Abbott Laboratories experienced an 11.4% decline in sales, amounting to $9.978 billion for the quarter. Despite this decrease, the company still outperformed the FactSet consensus of $9.972 billion in sales. It is important to note that the decline in sales was primarily due to a reduction in COVID-19 testing-related sales compared to the previous year.

Future Outlook

Despite challenges posed by the ongoing pandemic, Abbott Laboratories remains optimistic about its full-year performance. The company expects adjusted earnings per share (EPS) for the year to range between $4.30 and $4.50. Moreover, they anticipate double-digit growth in sales (excluding COVID testing) and estimate COVID testing-related sales to reach approximately $1.3 billion for the year.

Stock Performance

Year-to-date, Abbott Laboratories’ stock has experienced a 2.3% decline, contrasting with the 19% gain of the S&P 500 (SPX).

Willing to try automated trading?
See the best forex robots rating to make the right choice.
Explore the list here >

Related Articles

Leave a Comment

24 − = 19